Jan 9 (Reuters) - Astellas Pharma Inc
* Says it announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTEÂ®) antibody construct blinatumomab to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia
* In Japan, blinatumomab is jointly developed by Amgen Astellas BioPharma and the co
Source text in Japanese: goo.gl/iGVamQ
Further company coverage: (Beijing Headline News)
 